Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347176 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT02347176 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 204 participants.
The verdict
NCT02347176, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
Interventions
- OTHER Placebo
- BIOLOGICAL Tralokinumab Dose 1
- BIOLOGICAL Tralokinumab Dose 2
- BIOLOGICAL Tralokinumab Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2015-01-23 |
| Est. Completion | 2016-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02347176
The ClinicalTrials.gov registry entry for NCT02347176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02347176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02347176 about?
NCT02347176 is a clinical study titled "Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis". The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
What is the current status of trial NCT02347176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2015-01-23. Estimated completion is 2016-02-05.
What interventions are being tested in trial NCT02347176?
The interventions under investigation include: Placebo (OTHER), Tralokinumab Dose 1 (BIOLOGICAL), Tralokinumab Dose 2 (BIOLOGICAL), Tralokinumab Dose 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02347176?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.